FLJ43505 Inhibitors
FLJ43505 Inhibitors encompass a range of chemical compounds that act on various signaling pathways to decrease the functional activity of FLJ43505. Wortmannin and LY 294002 specifically target the PI3K/AKT signaling pathway, diminishing AKT phosphorylation and downstream signaling cascades that may be essential for FLJ43505 function. Rapamycin, by inhibiting mTOR, and PD 98059 and U0126, by targeting MEK1/2, disrupt central pathways in cell growth and proliferation, which could indirectly affect the expression or activity of FLJ43505. SB 203580 and SP600125, by modulating stress and inflammation via p38 MAPK and JNK pathways, respectively, can alter cellular responses that may involve FLJ43505. BML-275, through the inhibition of BMP signaling, and Y-27632, by impeding ROCK and thus cytoskeletal dynamics, could similarly lead to a decrease in FLJ43505 functional activity due to their roles in cell differentiation and motility.
Moreover, these inhibitors impact cellular processes that are potentially linked to FLJ43505's role in the cell. Imatinib and Dasatinib, as tyrosine kinase inhibitors, suppress growth factor signaling pathways that might be necessary for the proper functional activity of FLJ43505. Bafilomycin A1's role in inhibiting V-ATPase and subsequent autophagic processes could result in the altered turnover of proteins like FLJ43505. Each of these inhibitors operates through distinct biochemical mechanisms, yet collectively they serve to diminish the functional activity of FLJ43505 by targeting specific pathways or cellular processes that are logically implicated in the role of FLJ43505, without directly inhibiting its transcription or translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that impedes the phosphatidylinositol 3-kinase pathway, leading to the diminishment of AKT phosphorylation. Inhibition of this pathway can result in reduced activation of downstream targets that may be essential for the functional activity of FLJ43505. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that disrupts the mTORC1 signaling complex, a key component of cell growth and proliferation pathways. This can decrease the synthesis of proteins that are regulated by mTOR-dependent pathways, potentially including FLJ43505. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK1/2, which prevents the activation of the MAPK/ERK pathway. This can lead to a reduction in cellular proliferation signals that may indirectly affect the functional activity of FLJ43505. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A known inhibitor of p38 MAPK, affecting inflammatory response and stress-induced signaling pathways. This inhibition can result in the downregulation of proteins that are modulated by stress signals, which could include FLJ43505. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A chemical inhibitor of PI3K that blocks the AKT signaling pathway, potentially reducing the activity of downstream proteins such as FLJ43505, which may rely on AKT-mediated signaling for their function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A non-competitive inhibitor of MEK1/2, leading to suppression of the MAPK/ERK signaling cascade. By inhibiting this pathway, the compound could indirectly reduce the functional activity of FLJ43505. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the stress-activated MAPK pathway. Inhibition of JNK can decrease cellular responses to stress or cytokine signaling, potentially affecting FLJ43505 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that modulates the actin cytoskeleton dynamics. By inhibiting ROCK, this compound can alter cell motility and survival signals, potentially diminishing the role of FLJ43505 in these processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor which can suppress certain growth factor signaling pathways. This may result in decreased activation of downstream targets, potentially impacting the functional activity of FLJ43505. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
An inhibitor of the V-ATPase proton pump, affecting endosomal acidification and autophagy. By inhibiting this process, it can indirectly diminish the turnover or recycling of membrane proteins, potentially including FLJ43505. | ||||||